CClinicalTrials.gg
CompletedNCT03924479Updated Mar 22, 2024

Respiratory Muscle Function in Heart Failure

An interventional study of PowerBreathe (Breathing muscle training) in Heart Failure, Diastolic, sponsored by Mayo Clinic. Completed at 1 site in United States. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study is being done because investigators are trying to determine how respiratory muscle and lung function influence the exercise responses in heart failure and healthy participants. Further, the heart failure patients will participate in an intervention to improve their respiratory muscle function to determine if this improves exercise capacity.

Read the detailed description

The participants enrolled in this study will be asked to make 4 or 9 separate study visits. Healthy participants will perform 4 study visits and heart failure participants will perform 9 study visits.

During study visit 1, the participants will be asked to get a DEXA bone scan, perform pulmonary function tests, and exercise on a stationary bike at maximal exertion while breathing into a mouth piece. During the exercise test, a iodine-based dye will be injected via a venous catheter in the arm. Also, a thin balloon will be inserted through the nose into the esophagus.

During study visit 2, the participants will breathe the same way they did during exercise, but will be seated and not exercising. A thin balloon will be inserted through the nose into the esophagus.

During study visits 3 and 4, the participants will perform different respiratory muscle workouts at rest that will be at different intensities ranging from very easy to moderate for \~10 minutes. An iodine-based dye will be injected via a venous catheter in the arm.

The participant's with heart failure will then perform 8 weeks of breathing muscle training at home. After 3 weeks of breathing muscle training, the participants will return for study visit 5 where the training load will be adjusted. Following the 8 weeks of breathing muscle training, the heart failure participants will perform the same 4 study visits as outlined above.

02

Conditions studied

  • Heart Failure, Diastolic

Keywords

  • heart failure preserved ejection fraction
  • exercise
  • respiratory muscle
03

In context

Heart Failure

5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.

This study's enrollment of 30 is below the median of 72 across 3,736 interventional studies indexed under Heart Failure.

Browse Heart Failure studies →

Lead sponsor

Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.

Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Healthy subjects: Adults (≥21 years of age) in the absence of a history of HFpEF or HFrEF, pulmonary, neurologic, orthopedic, or other diseases affecting the neuromuscular system. Controls will be matched for age and sex.

All HFpEF patients will be managed by their primary care physician or cardiologist with additional review and oversight by Dr. Borlaug (Co-Investigator) prior to enrollment to ensure adequacy of inclusion and exclusion criteria and that participation in exercise testing and resistance exercise training is safe.

Inclusion criteria

Inclusion Criteria for HFpEF, includes:

  • Clinical diagnosis of HFpEF.
  • Patients with a history stable (no medication changes in past 6 weeks (w/duration of diagnosis >6 months).
  • New York Heart Association class I-III.
  • Current non-smokers with \<15 pack year history.
  • Non-pregnant women, and individuals who are able to exercise (i.e. without orthopedic limitations or neuromuscular disorders).

Exclusion criteria

Exclusion Criteria for all subjects, includes:

  • history of dangerous arrhythmias
  • body mass index >35 kg/m2
  • current smokers and/or smoking history >15 pack years
  • pregnant women
  • uremia, history of allergy to iodides
  • impaired renal function
  • creatinine value greater than or equal to 1.3 mg/dL (via clinical record within the past 6 months)
  • diagnosis of liver disease
  • individuals who are not able to engage in exercise
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Breathing muscle training

    The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing \~15 times each minute for 30 minutes at 40% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.

    Device: PowerBreathe (Breathing muscle training)

  • Sham comparator
    Sham breathing muscle training

    The breathing muscle training will consist of 7 sessions per week (1 per day) for 8 weeks. Each training session will consist of breathing \~15 times each minute for 30 minutes at 2%% of maximal breathing muscle strength, while using the breathing muscle trainer. During the inhalation, participants will be instructed to inhale as fast as they can, while exhalations will be performed at the participants discretion.

    Device: PowerBreathe (Breathing muscle training)

Interventions

  • DevicePowerBreathe (Breathing muscle training)

    The breathing muscle breathing training will consist of using the PowerBreathe training for 8 weeks. The PowerBreathe is an inspiratory pressure threshold trainer.The valve blocks the airflow until the threshold pressure is achieved by breathing in forcefully into the device.

    Also known as: PowerBreathe Device

06

What researchers measure

Primary outcomes

  1. Breathing muscle oxygen cost

    Breathing muscle oxygen uptake between heart failure and healthy participants

    Time frame: Year 1

  2. Respiratory muscle blood flow

    Breathing muscle blood flow between heart failure and healthy participants

    Time frame: Year 1

  3. Systolic and diastolic blood pressure

    Respiratory muscle workout-induced increases in systolic and diastolic blood pressure between heart failure and healthy participants

    Time frame: Year 1

  4. Breathing muscle oxygen cost

    Breathing muscle oxygen uptake from pre to post-breathing muscle training in heart failure participants

    Time frame: Year 2

  5. Respiratory muscle blood flow

    Breathing muscle blood flow rom pre to post-breathing muscle training in heart failure participants

    Time frame: Year 2

  6. Systolic and diastolic blood pressure

    Respiratory muscle workout-induced increases in systolic and diastolic blood pressure from pre to post-breathing muscle training in heart failure participants

    Time frame: Year 2

07

Study locations

1 site
  • Mayo Clinic in Rochester
    Rochester, Minnesota 55905, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03924479
Lead sponsor
Mayo Clinic
Responsible party
Thomas P. Olson, M.S., Ph.D. (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Apr 23, 2019
Start date
Nov 28, 2018
Primary completion
Mar 21, 2024
Completion
Mar 21, 2024
Last update
Mar 22, 2024

Study contacts

Thomas P Olson
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion